Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + sabatolimab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Azacitidine + sabatolimab is an investigational combination of azacitidine, a hypomethylating agent (HMA), and sabatolimab, a monoclonal antibody targeting TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), developed for the treatment of higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Azacitidine works by incorporating into DNA and RNA to induce hypomethylation and cytotoxicity in abnormal hematopoietic cells, while sabatolimab blocks TIM-3, modulating immune responses and aiming to enhance antitumor activity by inhibiting LSCs (leukemic stem cells) and reactivating immune effector cells. The combination is designed to provide durable clinical benefit for patients not eligible for intensive chemotherapy or stem cell transplant, with the rationale that sabatolimab may enhance the efficacy of azacitidine by overcoming immune resistance mechanisms[4][1].
- Other names
- MBG453 + azacitidinesabatolimab + azacitidine
02
Targets
DNMT (DNA methyltransferase)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on azacitidine + sabatolimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + sabatolimab.